Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18774078 | 0.81 | GAA (0.51) | GAAMAPTKDM4ENPSR1KMT2A | |
| SCHEMBL9883333 | 0.81 | GAA (0.51) | GAAMAPTKDM4ENPSR1KMT2A | |
| Hydrochloric Acid SCHEMBL28695724 | 0.79 | GAA (0.49) | GAAMAPTKDM4ENPSR1KMT2A | |
| SCHEMBL13696709 | 0.79 | GAA (0.52) | GAAMAPTKDM4ENPSR1KMT2A | |
| SCHEMBL10826850 | 0.78 | GAA (0.47) | GAAMAPTKDM4ENPSR1KMT2A | |
| Hydrochloric Acid SCHEMBL31578753 | 0.78 | GAA (0.50) | GAAMAPTKDM4ENPSR1KMT2A | |
| SCHEMBL21816341 | 0.78 | GAA (0.47) | GAAMAPTKDM4ENPSR1KMT2A | |
| SCHEMBL3930237 | 0.78 | GAA (0.47) | GAAMAPTKDM4ENPSR1KMT2A | |
| SCHEMBL3930232 | 0.78 | GAA (0.47) | GAAMAPTKDM4ENPSR1KMT2A | |
| SCHEMBL10826852 | 0.78 | GAA (0.47) | GAAMAPTKDM4ENPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654777-A2 | METHODS AND COMPOSITIONS SUITABLE FOR MANAGING BLOOD GLUCOSE IN ANIMALS | Nestec S.A. (CH) | 2013-10-30 | — | — | EP | claimed |
| WO-2012087742-A2 | METHODS AND COMPOSITIONS SUITABLE FOR MANAGING BLOOD GLUCOSE IN ANIMALS | NESTEC S.A. (CH) | 2012-06-28 | — | — | WO | claimed |
| US-20150259566-A1 | METHODS FOR PROVIDING A LOW GLOSS POLYURETHANE COATING ON A SUBSTRATE | BAYER MATERIALSCIENCE LLC (US) | 2015-09-17 | — | — | US | disclosed |
| WO-2015138227-A1 | METHODS FOR PROVIDING A LOW GLOSS POLYURETHANE COATING ON A SUBSTRATE | BAYER MATERIALSCIENCE LLC (US) | 2015-09-17 | — | — | WO | disclosed |
| US-8178516-B2 | Composition of 4-guanidinobenzoic acid HCl, a co-agent suitable for systemic administration solely via the oral route, antioxidants, vitamins, metabolites | Sylvan Labs, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | disclosed |
| CN-1293061-C | Novel branched substituted amino derivatives of 3-amino-1-phenyl-1H- [1,2,4] triazole, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2007-01-03 | — | — | CN | disclosed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | disclosed |
| US-6806282-B2 | HAVE AN ANTAGONISTIC ACTIVITY WITH RESPECT TO CORTICOTROPIN RELEASING FACTOR | SANOFI-SYNTHELABO (FR) | 2004-10-19 | — | — | US | disclosed |
| US-6746678-B1 | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments | SECANT PHARMA, LLC | 2004-06-08 | — | — | US | disclosed |
| EP-1242389-B1 | NOVEL BRANCHED SUBSTITUTED AMINO DERIVATIVES OF 3-AMINO-1-PHENYL-1H[1,2,4]TRIAZOL, METHODS FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI SYNTHELABO (FR) | 2004-04-21 | — | — | EP | disclosed |
| EP-0604641-B1 | USE OF A COMBINATION CONTAINING AN AMINE OR AMINE-RELATED DERIVATIVE OF BENZOIC ACID AND AN AMINO-POLYSACCHARIDE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2001044207-A2 | NOVEL BRANCHED SUBSTITUTED AMINO DERIVATIVES OF 3-AMINO-1-PHENYL-1H[1,2,4]TRIAZOL, METHODS FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2001-06-21 | — | — | WO | disclosed |
| CN-1065480-C | Multilayer article comprising a vulcanized elastomer directly bonded to a thermoplastic | ATOCHEM ELF SA (FR) | 2001-05-09 | — | — | CN | disclosed |
| CN-1119425-A | Multilayer article including a vulcanised elastomer directly combined with a thermoplastic | ATOCHEM ELF SA (FR) | 1996-03-27 | — | — | CN | disclosed |
| EP-0604641-A4 | COMPOSITION CONTAINING AMINE AND AMINE-RELATED DERIVATIVES OF BENZOIC ACID AND USES THEREFOR INCLUDING TREATING INFLAMMATORY DISEASES. | SHAPIRO HOWARD K (US) | 1995-08-02 | — | — | EP | disclosed |
| EP-0572560-A4 | USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY. | SHAPIRO HOWARD K (US) | 1995-04-26 | — | — | EP | disclosed |
| EP-0604641-A1 | COMPOSITION CONTAINING AMINE AND AMINE-RELATED DERIVATIVES OF BENZOIC ACID AND USES THEREFOR INCLUDING TREATING INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0572560-A1 | USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO, Howard, K. (US) | 1993-12-08 | — | — | EP | disclosed |
| WO-1992014456-A1 | USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | GAA 1432/4885MAPT 2712/4885KDM4E 2376/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | GAA 1423/4885MAPT 3087/4885KDM4E 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.